Lyseng-Williamson, Katherine A.; Foster, Rachel H. - In: PharmacoEconomics 22 (2004) 2, pp. 107-132
Infliximab (Remicade(R)), a biological disease-modifying antirheumatic drug (DMARD), binds to and inhibits the activity of tumour necrosis factor-alpha, which is thought to play an important role in the pathophysiology of rheumatoid arthritis. Intravenous infliximab plus methotrexate is...